DNA and RNA Banking Services Market Size, Share and Growth Outlook, 2026

DNA and RNA Banking Services Market Snapshot: Market Size, CAGR, and Growth Outlook (2021 to 2034)

The global DNA and RNA Banking Services Market size is forecast to increase from $9.73 Billion in 2026 to $15.28 Billion in 2034 at a CAGR of 5.8% between 2026 and 2034.

The DNA and RNA Banking Services market report provides detailed analysis and outlook of DNA and RNA Banking Services segments including By Service (Transportation Service, Processing Service, Storage Service, Quality Control Service, Data Storage), By Specimen (Blood Specimen, Buccal Swabs, Hair Follicles, Others), By Application (Therapeutics Application, Drug Discovery and Clinical Research, Clinical Diagnostics), By End User (Academic Research Institutes, Pharmaceutical and Biotechnology Companies, Hospitals and Diagnostic Centers) across global and regional markets. Further, analysis and outlook across 21 countries in North America, Europe, Asia Pacific, Middle East, Africa, and South America are provided in the study.

DNA and RNA Banking Services Industry Overview

Large-Scale Multi-Omics Biobanking Expansion

The DNA and RNA banking services market is increasingly driven by large-scale population biobanks integrating genomic, proteomic, and clinical datasets for advanced biomedical research. The UK Biobank has expanded its multi-omics infrastructure through a major initiative targeting measurement of up to 5,400 proteins across 600,000 biological samples, supported by a consortium of 14 biopharmaceutical companies under the UK Biobank Pharma Proteomics Project. This expansion strengthens the linkage between circulating protein expression profiles and whole-genome sequencing data generated from approximately 500,000 participants. These integrated datasets are being deployed through the UK Biobank Research Analysis Platform, enhancing accessibility for global researchers focused on disease prediction, biomarker discovery, and precision medicine modeling. Such developments reinforce the growing importance of centralized DNA and RNA repositories capable of supporting multi-layered biological data analysis at scale.

National Biobank Integration and Centralized Infrastructure Models

The DNA and RNA banking ecosystem is witnessing increased consolidation through national-level biobank integration programs aimed at reducing fragmentation and improving data standardization. The German Biobank Node has been structurally integrated into the Network of University Medicine under a unified German Biobank Network framework, consolidating tissue repositories, nucleic acid storage systems, and cross-site data collection infrastructure across university clinics. This centralized model enhances sample traceability, harmonization of biospecimen processing, and interoperability across research institutions. Such integrated biobank architectures support scalable access to high-quality DNA and RNA materials for translational research, clinical genomics, and pharmaceutical development pipelines, strengthening Europe’s position in global biobanking networks.

AI-Driven Genomic Data Interpretation and Predictive Analytics

Artificial intelligence applications are increasingly embedded within DNA and RNA banking services to enhance multi-omic data interpretation. AstraZeneca’s Centre for Genomics Research introduced MILTON, a machine learning-based platform designed to analyze multi-omic datasets derived from large biobank cohorts. The system processes hundreds of thousands of participant profiles, integrating clinical variables with plasma protein signatures to identify undiagnosed disease cohorts and improve biomarker discovery. AI-enabled stratification of genomic and proteomic datasets is accelerating predictive analytics in disease progression modeling, enabling more refined target identification and supporting precision drug development workflows across the DNA and RNA banking services landscape.

DNA and RNA Banking Services Market Trends, Growth Drivers, Competitive Landscape, and Future Opportunities

The global DNA and RNA Banking Services market is witnessing increasing investments in innovation, product development, digital transformation, artificial intelligence integration, healthcare infrastructure expansion, and strategic partnerships across developed and emerging economies. Key Companies in the industry include- Azenta Life Sciences (Brooks Life Sciences), Thermo Fisher Scientific Inc., Qiagen N.V., Hamilton Company, BioStorage Technologies, Inc. (Azenta), Infinity BiologiX (IBX), Teva Pharmaceutical Industries Ltd., Biovault Family, Cryo-Cell International, Inc., SciSafe (BioLife Solutions). The DNA and RNA Banking Services market is expected to remain one of the most closely watched segments in the global healthcare industry, with companies focusing on niche market segments. As healthcare systems across the US, Europe, Asia-Pacific, Latin America, and Middle East & Africa continue to prioritize efficiency, access, and innovation, the DNA and RNA Banking Services industry outlook remains shaped by rising healthcare expenditure, demographic change, digital transformation, and product innovation.
The report provides detailed market analysis including-

• Growth DNA and RNA Banking Services Market size outlook across 3 scenarios- High growth, reference, and Low growth cases

• Market Trends, Drivers, Potential Opportunities, and Challenges faced by DNA and RNA Banking Services companies

• Porter’s Five forces analysis- Bargaining power of buyers and sellers, Threat of Substitutes and new entrants, and Intensity of competitive rivalry

• Detailed SWOT Analysis of global and regional DNA and RNA Banking Services markets

• Competitive analysis including business description, product analysis, and financial profiles

• Key country specific analysis detailing key factors shaping the short-term and long-term outlook

• Recent industry developments and news including mergers, acquisitions, product launches, expansions, and company announcements

DNA and RNA Banking Services Market Competitive Benchmarking and Company Analysis

Leading companies in DNA and RNA Banking Services industry include- Azenta Life Sciences (Brooks Life Sciences), Thermo Fisher Scientific Inc., Qiagen N.V., Hamilton Company, BioStorage Technologies, Inc. (Azenta), Infinity BiologiX (IBX), Teva Pharmaceutical Industries Ltd., Biovault Family, Cryo-Cell International, Inc., SciSafe (BioLife Solutions). The DNA and RNA Banking Services market remains moderately to highly fragmented, with competition expected to intensify as companies accelerate investments in innovation, geographic expansion, strategic partnerships, and portfolio diversification through 2034. In developed markets such as the United States, Germany, France, the United Kingdom, and Canada, competition is increasingly centered on innovation, reimbursement positioning, and value-based healthcare solutions. Meanwhile, emerging markets including China, India, Brazil, and countries across the Middle East and Africa continue to present significant opportunities for expansion due to rising healthcare expenditure, growing patient populations, and increasing access to healthcare services.

What to expect in US DNA and RNA Banking Services Markets in 2026 and beyond- Market Size, Share, Growth Rate, and Forecast to 2034

The US healthcare expenditure is forecast to reach $8.2 Trillion in 2034 from $5.5 Trillion in 2026 based on the National Health Expenditure Accounts (NHEA) data. With an aging population, rising chronic disease burden, and increasing migration toward minimally invasive and outpatient care, the DNA and RNA Banking Services market remains one of the strongest-performing segments in the country.
The US DNA and RNA Banking Services Companies are opting new business models, optimized pricing models, industry partnerships, and AI-enabled back end transformations to enhance efficiency and cost management. The US DNA and RNA Banking Services market faces successive waves of challenging trends, with strong opportunities across select segments. The CMS plan to implement Medicaid from 2027 is driving states to build eligibility verification systems throughout 2026. Looking ahead to 2034, we anticipate stronger results underpinned by opportunities exist across DNA and RNA Banking Services industry. On the medical device front, over 7,000 device manufacturers continue to gain from increasing demand from demand for implantable devices, surgical instruments, monitoring equipment, and diagnostic systems.

Canada- Proximity to the US and healthcare similarities to EU5 countries fuel sales of Canadian DNA and RNA Banking Services markets

Canada's strong DNA and RNA Banking Services sales performance is underpinned by an aging population and a well-developed healthcare infrastructure. Steady growth in new brand spending in rural and urban locations fuel the long-term prospects of small and medium-sized enterprises across medical, diagnostic, and therapeutic devices. The Canadian DNA and RNA Banking Services market presents significant opportunities for U.S. exporters of medical devices, with the U.S. being Canada’s largest trading partner for this sector. Potential advantages including specialized materials, advanced manufacturing techniques, and digital technologies support the launch of new products in the country.

Germany DNA and RNA Banking Services Trends and Perspectives to 2034- Financial sustainability, hospital restructuring, demographic pressures, and digitization of care delivery continue to shape the German healthcare industry.

Germany continues to remain the largest DNA and RNA Banking Services market in Europe, driven by over €600 Billion healthcare expenditure, €12 Billion medical device R&D expenditure, statutory health insurance system covering 90% German population, nationwide rollout of the electronic patient record (ePA), and large-volume of DNA and RNA Banking Services population. In particular, Research and development in Germany fuels the commercialization of cutting-edge technologies. Companies across the Germany DNA and RNA Banking Services industry value chain are focusing on both domestic markets and exports. The country is also driving digital adoption with the Hospital Future Act driving hospitals to upgrade their information systems by 2027. Over the forecast period, aging population, rising healthcare costs, and increasing procedural volumes drive the DNA and RNA Banking Services market outlook.

France Market Size, Growth Rate, and Forecast Analysis to 2034- Universal healthcare system, high public healthcare expenditure, and strong government support DNA and RNA Banking Services sales through 2034

France DNA and RNA Banking Services companies are emphasizing on opportunities for rapid, at-scale innovation to boost profitability over the long-term. The country’s National Health Insurance spending target (ONDAM) estimates 3.7% growth in the country’s healthcare expenditure. Over the forecast period, expenditure control measures, chronic disease management initiatives, workforce reforms, and efforts to improve system efficiency drive the long-term prospects.
The biggest 2026 policy frame is the PLFSS 2026. The law sets the Maladie branch spending target at €271.4 billion for 2026 and fixes the ONDAM at €117.5 billion for city care, €112.8 billion for health establishments, and €18.3 billion for elderly-care establishments and services. France’s market is also being pulled by demographics. INSEE estimates that on 1 January 2026 France had 69.1 million inhabitants, with 22% aged 65 or over. INSEE also reported that 2025 births were 645,000 and deaths were 651,000, producing a negative natural balance of about 6,000 for the first time since the end of the Second World War.

UK DNA and RNA Banking Services Market Size, Share, and Growth Projections to 2034- Rapid growth driven by new and existing brands across the industry value chain

Small high-need consumer segments remain key priority of DNA and RNA Banking Services distributors in the UK industry. Continuous launch of new products coupled with high expenditures support the market outlook. The UK Government financing remains the dominant funding source at 81.3% of total healthcare expenditure, or £280 billion in 2025. According to the ONS, total healthcare spending grew 7.7% nominally and 3.9% in real terms from 2024 to 2025. Similarly, out-of-pocket spending was £49 billion (14.1%) and voluntary health insurance was £9.5 billion (2.8%). The market is driven by rapid digital adoption with NHS England’s plan to give more than 500,000 staff access to new AI tools.

China DNA and RNA Banking Services Market Growth Drivers, Revenue Trends, and Forecast- Medical insurance coverage is rapidly expanding over the past few years

China DNA and RNA Banking Services market is undergoing a structural shift from hospital-centric care toward a more integrated system emphasizing primary care, outpatient services, and long-term care. Chinese local players are emerging as a strong pillar of DNA and RNA Banking Services industry, offering opportunities for both competition and partnership. Over the forecast period, new and innovative product launches remain key elements driving market outlook. China's healthcare industry is increasingly centered on expanding healthcare capacity, improving access to advanced treatments, and reducing dependence on imported technologies.
The National Healthcare Security Administration reported that by end-2024, China’s basic medical insurance covered 1.32662 billion people and the coverage rate was 95%. Regional disparities in consumer spending trends continue to become more pronounced in the Chinese DNA and RNA Banking Services industry. Over the forecast period, demand will keep shifting toward geriatrics, chronic disease management, rehabilitation, long-term care, and outpatient care, while pricing pressure will remain intense in drugs and consumables because reimbursement.

India DNA and RNA Banking Services Market Landscape: Current Size and Long-Term Growth Outlook - Increased pricing pressures in US market is encouraging domestic vendors to expand across India

Indian DNA and RNA Banking Services market is witnessing the rapid emergence of an ecosystem that brings together diverse companies across the industry value chain. Further, large-scale healthcare public and private investments and a steady growth in chronic conditions is driving sales of pharmaceuticals and medical devices. Further, non-retail channel is experiencing volume decrease and patients are migrating to the retail. Indian medical device firms are also combining precision engineering with lower labor costs to make world-class diagnostics, robotics, and critical care devices.

Brazil DNA and RNA Banking Services market remains price-driven, with products domestically manufactured and accessibility offering potential opportunities

Healthcare expenditure in Brazil exceeds 10% of GDP, with the country among the highest healthcare spenders in Latin America. ANS reported 53.2 million medical-plan beneficiaries in December 2025, while IBGE projects a steady rise in older-age cohorts, with people aged 60+ already representing about 23% of the population. The price sensitive market access is broad through the public system, private coverage adds a sizeable premium layer, and reimbursement, procurement, and hospital efficiency remain key buying drivers.

Middle East and Africa DNA and RNA Banking Services Industry Trends and Perspectives to 2034

According to the World Bank, the Middle East and North Africa population exceeds 500 million, while Sub-Saharan Africa's population exceeds 1.2 billion, making the broader MEA region one of the fastest-growing healthcare demand centers globally. The GCC countries including Saudi Arabia, United Arab Emirates, Qatar, and Kuwait continue to account for a disproportionately large share of regional healthcare spending. Government-led programs such as Saudi Arabia's Vision 2030 are accelerating investments in hospital infrastructure, private-sector participation, medical technology adoption, and healthcare digitalization. On the other hand, South Africa, Egypt, Nigeria, and Kenya remain key healthcare markets due to their large populations, expanding private healthcare sectors, and growing investments in healthcare delivery systems.

DNA and RNA Banking Services Market Segmentation

By Service
Transportation Service
Processing Service
Storage Service
Quality Control Service
Data Storage
By Specimen
Blood Specimen
Buccal Swabs
Hair Follicles
Others
By Application
Therapeutics Application
Drug Discovery and Clinical Research
Clinical Diagnostics
By End User
Academic Research Institutes
Pharmaceutical and Biotechnology Companies
Hospitals and Diagnostic Centers

Top Companies in DNA and RNA Banking Services Industry

Azenta Life Sciences (Brooks Life Sciences)
Thermo Fisher Scientific Inc.
Qiagen N.V.
Hamilton Company
BioStorage Technologies, Inc. (Azenta)
Infinity BiologiX (IBX)
Teva Pharmaceutical Industries Ltd.
Biovault Family
Cryo-Cell International, Inc.
SciSafe (BioLife Solutions)

Countries Included

• North America- US, Canada, Mexico

• Europe- Germany, France, UK, Spain, Italy, Nordics, Others

• Asia Pacific- China, India, Japan, South Korea, Australia, Southeast Asia, Others

• Latin America- Brazil, Argentina, Others

• Middle East and Africa- Saudi Arabia, UAE, Other Middle East, South Africa, Other Africa

Latest Market Updates In Healthcare

Support this report with fresh, same-industry updates that strengthen topical depth and internal linking.

Market Update

Rise of Functional and Clinical-Grade Skincare

The rising geopolitical and tariff-related uncertainties, in particular, amidst United States’ renewed protectionist trade stance continues to driv...

June 2025